France Cell and Gene Therapy CDMO Market Industry Trends and Forecast to 2034: Segmented by (Service, Product, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
France · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$190.0 MnPlaceholder estimate
Estimate 2025$226.2 Mn2.6% of the global market
Projected 2034$1.08 Bn 378.5%Adds $856.1 Mn over 9 forecast years
CAGR 2025–203419.0%Faster than 87% of 180 Pharmaceuticals markets here
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The France Cell and Gene Therapy CDMO Market Analysis Executive Summary
Cell and gene therapy CDMOs are contract companies that develop and manufacture cell and gene therapies for biotech and pharma firms.
Key segments of the cell and Gene Therapy CDMO market include service (Process Development, Clinical Manufacturing and Commercial Manufacturing) and product (Viral Vectors, Cell Therapies and Plasmid DNA).
France Cell and Gene Therapy CDMO market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
France Cell and Gene Therapy CDMO Market Dynamics
Market Growth Drivers
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the cell and Gene Therapy CDMO market.
Opportunity
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the cell and Gene Therapy CDMO market.
Market Restraints
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the cell and Gene Therapy CDMO market. Payers are still working out how to pay for one-time cures.
Competitive Landscape for Cell and Gene Therapy CDMO Market in France
The cell and Gene Therapy CDMO market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Cell and Gene Therapy CDMO Market in France
Cell and Gene Therapy CDMO in France: rules and payment
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency.[1] National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover.[2]
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for cell and Gene Therapy CDMO. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in France.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Service
4.2 By Product
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Lonza
7.2 Catalent
7.3 Charles River Laboratories
7.4 WuXi AppTec
7.5 AGC Biologics
7.6 Samsung Biologics
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The cell and Gene Therapy CDMO market can be segmented based on various criteria, including service, product and end user. Here's a breakdown of the market segmentation
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Cell and Gene Therapy CDMO in context
France compared
Health spending per person: 5,327 US$ per person (2024). World: 1,317 US$ per person (2023). 3rd highest of the 6 countries we cover in Europe.[1]
Doctors: 3.28 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 6th highest of the 6 countries we cover in Europe.[2]
People aged 65 and over: 22.5% of people (2025). World: 10.4% of people (2025). 3rd highest of the 6 countries we cover in Europe.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
How big is the Cell and Gene Therapy CDMO market in France?
Placeholder estimate: about $226.2 Mn in 2025, rising to about $1.08 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Cell and Gene Therapy CDMO market in France growing?
Placeholder estimate: about 19.0% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Cell and Gene Therapy CDMO market report cover?
The report splits the market by service (Process Development, Clinical Manufacturing, Commercial Manufacturing, Testing), product (Viral Vectors, Cell Therapies, Plasmid DNA) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Cell and Gene Therapy CDMO market?
Key players include Lonza Ltd, Catalent, Charles River Laboratories, WuXi AppTec, AGC Biologics and Samsung Biologics.
What is driving the Cell and Gene Therapy CDMO market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the cell and Gene Therapy CDMO market.
Who regulates Cell and Gene Therapy CDMO in France?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency. Source: ANSM, French medicines agency. Checked 14 Nov 2026.
How is healthcare paid for in France?
National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover. Source: Assurance Maladie (ameli.fr). Checked 14 Nov 2026.
France 
Germany
Russia
US
China
Canada
Japan
Brazil
UK
Italy
Ecuador
Spain
Saudi Arabia
India
Mexico
New Zealand
Australia
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Thailand
Singapore
Kenya